Annual CFF:
$51.31M-$428.39M(-89.30%)Summary
- As of today, MLTX annual cash from financing is $51.31 million, with the most recent change of -$428.39 million (-89.30%) on December 31, 2024.
- During the last 3 years, MLTX annual cash from financing has risen by +$8.05 million (+18.60%).
- MLTX annual cash from financing is now -89.30% below its all-time high of $479.70 million, reached on December 31, 2023.
Performance
MLTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly CFF:
$0.00-$73.12M(-100.00%)Summary
- As of today, MLTX quarterly cash from financing is $0.00, with the most recent change of -$73.12 million (-100.00%) on June 30, 2025.
- Over the past year, MLTX quarterly cash from financing has stayed the same.
- MLTX quarterly cash from financing is now -100.00% below its all-time high of $451.29 million, reached on June 30, 2023.
Performance
MLTX Quarterly Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$73.46M$0.00(0.00%)Summary
- As of today, MLTX TTM cash from financing is $73.46 million, unchanged on June 30, 2025.
- Over the past year, MLTX TTM cash from financing has dropped by -$5.94 million (-7.48%).
- MLTX TTM cash from financing is now -86.16% below its all-time high of $530.68 million, reached on March 31, 2024.
Performance
MLTX TTM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
MLTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -89.3% | 0.0% | -7.5% |
| 3Y3 Years | +18.6% | -100.0% | -45.7% |
| 5Y5 Years | -56.0% | - | - |
MLTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -89.3% | +18.6% | -100.0% | at low | -86.2% | +43.2% |
| 5Y | 5-Year | -89.3% | +18.6% | -100.0% | +100.0% | -86.2% | +69.8% |
| All-Time | All-Time | -89.3% | +18.6% | -100.0% | +100.0% | -86.2% | +69.8% |
MLTX Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $0.00(-100.0%) | $73.46M(0.0%) |
| Mar 2025 | - | $73.12M(>+9900.0%) | $73.46M(+43.2%) |
| Dec 2024 | $51.31M(-89.3%) | $150.70K(-17.7%) | $51.31M(-35.5%) |
| Sep 2024 | - | $183.10K(>+9900.0%) | $79.58M(+0.2%) |
| Jun 2024 | - | $0.00(-100.0%) | $79.39M(-85.0%) |
| Mar 2024 | - | $50.98M(+79.4%) | $530.68M(+10.6%) |
| Dec 2023 | $479.70M | $28.42M(>+9900.0%) | $479.70M(+6.3%) |
| Sep 2023 | - | $0.00(-100.0%) | $451.29M(0.0%) |
| Jun 2023 | - | $451.29M(>+9900.0%) | $451.29M(+331.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | $0.00(-100.0%) | $104.69M(-12.5%) |
| Dec 2022 | $119.69M(+176.7%) | $3800.00(>+9900.0%) | $119.69M(-11.1%) |
| Sep 2022 | - | $0.00(-100.0%) | $134.69M(-0.4%) |
| Jun 2022 | - | $104.69M(+597.7%) | $135.19M(+131.8%) |
| Mar 2022 | - | $15.00M(+0.0%) | $58.32M(+34.8%) |
| Dec 2021 | $43.26M(-62.9%) | $15.00M(+2910.0%) | $43.26M(-70.1%) |
| Sep 2021 | - | $498.30K(-98.2%) | $144.92M(+0.3%) |
| Jun 2021 | - | $27.82M(>+9900.0%) | $144.42M(+23.9%) |
| Mar 2021 | - | -$58.10K(-100.0%) | $116.59M(-0.0%) |
| Dec 2020 | $116.65M | $116.65M | $116.65M |
FAQ
- What is MoonLake Immunotherapeutics annual cash from financing?
- What is the all-time high annual cash from financing for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics annual cash from financing year-on-year change?
- What is MoonLake Immunotherapeutics quarterly cash from financing?
- What is the all-time high quarterly cash from financing for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics quarterly cash from financing year-on-year change?
- What is MoonLake Immunotherapeutics TTM cash from financing?
- What is the all-time high TTM cash from financing for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics TTM cash from financing year-on-year change?
What is MoonLake Immunotherapeutics annual cash from financing?
The current annual cash from financing of MLTX is $51.31M
What is the all-time high annual cash from financing for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high annual cash from financing is $479.70M
What is MoonLake Immunotherapeutics annual cash from financing year-on-year change?
Over the past year, MLTX annual cash from financing has changed by -$428.39M (-89.30%)
What is MoonLake Immunotherapeutics quarterly cash from financing?
The current quarterly cash from financing of MLTX is $0.00
What is the all-time high quarterly cash from financing for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high quarterly cash from financing is $451.29M
What is MoonLake Immunotherapeutics quarterly cash from financing year-on-year change?
Over the past year, MLTX quarterly cash from financing has changed by $0.00 (0.00%)
What is MoonLake Immunotherapeutics TTM cash from financing?
The current TTM cash from financing of MLTX is $73.46M
What is the all-time high TTM cash from financing for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high TTM cash from financing is $530.68M
What is MoonLake Immunotherapeutics TTM cash from financing year-on-year change?
Over the past year, MLTX TTM cash from financing has changed by -$5.94M (-7.48%)